Alabama is currently home to 1237 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690
Recruiting
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Retina Consultants of Alabama, Birmingham, Alabama
Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Register for Updates
In-Office Clinical Study of the Solo+ TTD
NCT05741333
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the Solo+ Tympanostomy Tube Device (Solo+ TTD) for the placement of tympanostomy tubes in paediatric patients undergoing a tympanostomy procedure.
Gender:
ALL
Ages:
Between 6 months and 13 years
Trial Updated:
04/15/2025
Locations: Southern Head & Neck Surgery, Alexander City, Alabama
Conditions: Ear Infection, Otitis Media
Register for Updates
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Accel Research Sites Network - Birmingham- Site Number : 8400003, Birmingham, Alabama
Conditions: Systemic Lupus Erythematosus
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham, Alabama
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340
Recruiting
The main purpose of this study is to: * Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Alabama_6th Ave, Birmingham, Alabama
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
NCT06595420
Recruiting
The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it becomes permanent. The study will compare these markers in people with CF over time and during the treatment of lung flare-ups. It will also compare the blood and urine samples obtained from people without CF. The comparison aims to better understand the impact of cystic... Read More
Gender:
ALL
Ages:
7 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
Register for Updates
PREVENT ALL ALS Study
NCT06581861
Recruiting
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The cl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Sensory Filtering in the Human Basal Ganglia as a Mechanism of Parkinson's Disease
NCT05482126
Recruiting
The investigators are investigating the brain activity associated with sensory information in movement disorders in order to improve treatment of these symptoms beyond what is currently available.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/14/2025
Locations: The University of Alabama at Birmingham Hospital, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
NCT05434689
Recruiting
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administrat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
Register for Updates
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
NCT05404750
Recruiting
People living with HIV (PLWH) who use drugs experience significant health disparities including lower rates of retention in HIV care and higher rates of unsuppressed viral load, resulting in secondary infections and increased mortality. The proposed study will used mixed methods to explore (a) the relationship between healthcare providers' attitudes towards working with PLWH who use drugs and providers' acceptance and practice of structural and relational harm reduction; (b) the degree to which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Human Immunodeficiency Virus, Substance Use, Stigma, Social
Register for Updates
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Recruiting
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/14/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Register for Updates